trichostatin A

Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.

Cross Reference

Introduction

To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with trichostatin A?

trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with trichostatin A

MeSH term MeSH ID Detail
Adenomyosis D062788 1 associated lipids
Neoplasm Micrometastasis D061206 1 associated lipids
Visceral Pain D059265 1 associated lipids
Inflammatory Breast Neoplasms D058922 2 associated lipids
Capsule Opacification D058442 1 associated lipids
Intervertebral Disc Degeneration D055959 1 associated lipids
Small Cell Lung Carcinoma D055752 2 associated lipids
Primary Myelofibrosis D055728 6 associated lipids
Classical Lissencephalies and Subcortical Band Heterotopias D054221 1 associated lipids
Atherosclerosis D050197 85 associated lipids
Per page 10 20 50 100 | Total 139

PubChem Associated disorders and diseases

What pathways are associated with trichostatin A

Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with trichostatin A?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with trichostatin A?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with trichostatin A?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with trichostatin A?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with trichostatin A?

Mouse Model

Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).

Xenograft Model

Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).

Cancer Model

Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with trichostatin A

Download all related citations
Per page 10 20 50 100 | Total 3126
Authors Title Published Journal PubMed Link
Sakuma M et al. Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer. 2007 Cancer Sci. pmid:17270028
Chikamatsu K et al. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck. 2013 Cancer Sci. pmid:23992541
Furumai R et al. Histone deacetylase inhibitors block nuclear factor-κB-dependent transcription by interfering with RNA polymerase II recruitment. 2011 Cancer Sci. pmid:21299717
Yamada Y et al. Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer. 2003 Cancer Sci. pmid:12824880
Okada T et al. Identification of genes specifically methylated in Epstein-Barr virus-associated gastric carcinomas. 2013 Cancer Sci. pmid:23829175
Bayart E et al. A major role for mitotic CDC2 kinase inactivation in the establishment of the mitotic DNA damage checkpoint. 2004 Cancer Res. pmid:15604258
Zhao LY et al. An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis. 2006 Cancer Res. pmid:17018599
Yang X et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. 2001 Cancer Res. pmid:11585728
Luo W et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. 2010 Cancer Res. pmid:20587525
Sasaki Y et al. p53 negatively regulates the hepatoma growth factor HDGF. 2011 Cancer Res. pmid:22006999
Phan D et al. Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. 2004 Cancer Res. pmid:15126343
Wang X et al. Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. 2009 Cancer Res. pmid:19752087
Wei M et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. 2005 Cancer Res. pmid:16322213
Hatjiharissi E et al. Proteomic analysis of waldenstrom macroglobulinemia. 2007 Cancer Res. pmid:17440091
Mariadason JM et al. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. 2000 Cancer Res. pmid:10969808
Hellebrekers DM et al. Identification of epigenetically silenced genes in tumor endothelial cells. 2007 Cancer Res. pmid:17483324
James SY et al. Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. 2003 Cancer Res. pmid:12839938
Noh EJ et al. Methyl CpG-binding domain protein 3 mediates cancer-selective cytotoxicity by histone deacetylase inhibitors via differential transcriptional reprogramming in lung cancer cells. 2005 Cancer Res. pmid:16357148
Fahrner JA et al. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. 2002 Cancer Res. pmid:12499261
Terui T et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. 2003 Cancer Res. pmid:14695212
Shah S et al. Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. 2012 Cancer Res. pmid:22258452
Setiadi AF et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. 2008 Cancer Res. pmid:19047136
Lau QC et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. 2006 Cancer Res. pmid:16818622
Foltz G et al. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. 2006 Cancer Res. pmid:16818640
Mori T et al. Estrogen receptor-alpha methylation predicts melanoma progression. 2006 Cancer Res. pmid:16818643
Sharma D et al. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. 2006 Cancer Res. pmid:16778215
Shi J et al. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. 2007 Cancer Res. pmid:17616702
Su Y et al. Human RecQL4 helicase plays critical roles in prostate carcinogenesis. 2010 Cancer Res. pmid:21045146
Sugita K et al. Morphological reversion of sis-transformed NIH3T3 cells by trichostatin A. 1992 Cancer Res. pmid:1727377
Qi H and Ratnam M Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. 2006 Cancer Res. pmid:16740727
Yoshida M et al. Effects of trichostatins on differentiation of murine erythroleukemia cells. 1987 Cancer Res. pmid:2439196
Ibanez de Caceres I et al. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. 2006 Cancer Res. pmid:16707423
Imre G et al. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. 2006 Cancer Res. pmid:16707469
Singal R et al. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. 2001 Cancer Res. pmid:11406558
Brest P et al. Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET. 2007 Cancer Res. pmid:18056459
Maecker HL et al. p53 promotes selection for Fas-mediated apoptotic resistance. 2000 Cancer Res. pmid:10969818
Badia E et al. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. 2000 Cancer Res. pmid:10945620
Su GH et al. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. 2000 Cancer Res. pmid:10866300
Blagosklonny MV et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. 2005 Cancer Res. pmid:16103091
Lin F et al. Unique anti-activator protein-1 activity of retinoic acid receptor beta. 2000 Cancer Res. pmid:10866321
Sirchia SM et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. 2002 Cancer Res. pmid:11980632
Hsu PY et al. Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. 2009 Cancer Res. pmid:19549897
Heller G et al. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. 2008 Cancer Res. pmid:18172295
Shin JY et al. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. 2000 Cancer Res. pmid:10667572
Kretzner L et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. 2011 Cancer Res. pmid:21502403
Saunders N et al. Histone deacetylase inhibitors as potential anti-skin cancer agents. 1999 Cancer Res. pmid:9927053
Ramsey MR et al. Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. 2011 Cancer Res. pmid:21527555
Medina V et al. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. 1997 Cancer Res. pmid:9288776
Harada K et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. 2002 Cancer Res. pmid:12384554
Wilson AJ et al. Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. 2002 Cancer Res. pmid:12414619
Ho WC et al. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. 2005 Cancer Res. pmid:15899819
Tran T et al. Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. 2005 Cancer Res. pmid:15899836
Kim MS et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. 2003 Cancer Res. pmid:14612526
Majid S et al. Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. 2010 Cancer Res. pmid:20332239
Liu LT et al. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. 2003 Cancer Res. pmid:12810630
Allison SJ and Milner J Loss of p53 has site-specific effects on histone H3 modification, including serine 10 phosphorylation important for maintenance of ploidy. 2003 Cancer Res. pmid:14583461
Sowa Y et al. Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. 1999 Cancer Res. pmid:10485470
Lin YC et al. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. 2008 Cancer Res. pmid:18381445
Ju R and Muller MT Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. 2003 Cancer Res. pmid:12782595
Wang J et al. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. 1999 Cancer Res. pmid:10383127
Myzak MC et al. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. 2004 Cancer Res. pmid:15313918
Kim TY et al. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. 2006 Cancer Res. pmid:16885346
Xiong Y et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. 2005 Cancer Res. pmid:15805266
Ferrara FF et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. 2001 Cancer Res. pmid:11196162
Kumakura S et al. Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells. 2005 Cancer Res. pmid:15805278
Zhao S et al. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells. 2003 Cancer Res. pmid:12750289
Nishigaki M et al. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. 2005 Cancer Res. pmid:15781621
Bai J et al. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. 2005 Cancer Res. pmid:15781649
Yang X et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. 2000 Cancer Res. pmid:11156387
Rahmani M et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. 2005 Cancer Res. pmid:15781658
Stiehl DP et al. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation. 2007 Cancer Res. pmid:17332356
Kim M et al. LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer. 2008 Cancer Res. pmid:18757430
Mori T et al. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. 2005 Cancer Res. pmid:15753377
Nervi C et al. Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. 2001 Cancer Res. pmid:11245412
Zhu WG et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. 2001 Cancer Res. pmid:11245429
Pellicciotta I et al. Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition. 2008 Cancer Res. pmid:18829567
Mousa SA et al. Stress resistant human embryonic stem cells as a potential source for the identification of novel cancer stem cell markers. 2010 Cancer Lett. pmid:19733430
Sugimoto S et al. Expression and regulation of tumor suppressor gene maspin in human bladder cancer. 2004 Cancer Lett. pmid:14732229
Li Y et al. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. 2012 Cancer Lett. pmid:22266186
Jung EJ et al. Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir. 2007 Cancer Lett. pmid:16647201
Davies GF et al. Troglitazone inhibits histone deacetylase activity in breast cancer cells. 2010 Cancer Lett. pmid:19699029
Hostetter CL et al. Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity. 2009 Cancer Lett. pmid:19013015
Francisco R et al. Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. 2012 Cancer Lett. pmid:22186300
Pitta CA et al. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance. 2013 Cancer Lett. pmid:23752064
Nair AR et al. Paradoxical effects of trichostatin A: inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. 2001 Cancer Lett. pmid:11295287
Zhang Q et al. Interferon regulatory factor 8 functions as a tumor suppressor in renal cell carcinoma and its promoter methylation is associated with patient poor prognosis. 2014 Cancer Lett. pmid:25109451
Liu RF et al. Down-regulation of miR-517a and miR-517c promotes proliferation of hepatocellular carcinoma cells via targeting Pyk2. 2013 Cancer Lett. pmid:23142219
Chen H et al. LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth factor permissive microenvironment in nasopharyngeal carcinoma. 2012 Cancer Lett. pmid:22743615
Januchowski R et al. Trichostatin A down-regulate DNA methyltransferase 1 in Jurkat T cells. 2007 Cancer Lett. pmid:16624484
Koh E et al. Trichostatin A and 5-aza-2'-deoxycytidine switch S1P from an inhibitor to a stimulator of motility through epigenetic regulation of S1P receptors. 2007 Cancer Lett. pmid:17189669
Bharadwaj S and Prasad GL Tropomyosin-1, a novel suppressor of cellular transformation is downregulated by promoter methylation in cancer cells. 2002 Cancer Lett. pmid:12065096
Bazhin AV et al. Expression of GAGE family proteins in malignant melanoma. 2007 Cancer Lett. pmid:17194529
Al-Rayyan N et al. 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines. 2014 Cancer Lett. pmid:24513177
Chen Z et al. Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. 2002 Cancer Lett. pmid:12406558
Gálfi P et al. Apoptosis sensitivity is not correlated with sensitivity to proliferation inhibition by the histone deacetylase inhibitors butyrate and TSA. 2002 Cancer Lett. pmid:12406559
Ryu JK et al. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. 2006 Cancer Lett. pmid:16009488
Jung JW et al. Effects of the histone deacetylases inhibitors sodium butyrate and trichostatin A on the inhibition of gap junctional intercellular communication by H2O2- and 12-O-tetradecanoylphorbol-13-acetate in rat liver epithelial cells. 2006 Cancer Lett. pmid:16337085
Ohike N et al. Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. 2003 Cancer Lett. pmid:12969792
Hoebeeck J et al. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. 2009 Cancer Lett. pmid:18819746
Meng CF et al. Role of histone modifications and DNA methylation in the regulation of O6-methylguanine-DNA methyltransferase gene expression in human stomach cancer cells. 2010 Cancer Invest. pmid:19857042